- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT04606381
Um Estudo da Administração Subcutânea (SC) de Amivantamab para o Tratamento de Malignidades Sólidas Avançadas (PALOMA)
Um estudo aberto, multicêntrico, de fase 1b de escalonamento de dose para avaliar a segurança e a farmacocinética da administração subcutânea de amivantamab, um EGFR biespecífico humano e anticorpo cMet para o tratamento de neoplasias sólidas avançadas
The purpose of this study is to assess the feasibility of subcutaneous (SC) administration of amivantamab based on safety and pharmacokinetics and determine a dose, dose regimen and formulation for amivantamab SC delivery.
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Tipo de estudo
Inscrição (Real)
Estágio
- Fase 1
Contactos e Locais
Locais de estudo
-
-
Ontario
-
Toronto, Ontario, Canadá, M5G 2M9
- University Health Network
-
-
-
-
-
Cheongju-si, Coréia do Sul, 28644
- Chungbuk National University Hospital
-
Seongnam-si, Coréia do Sul, 13620
- Seoul National University Bundang Hospital
-
Seoul, Coréia do Sul, 03722
- Severance Hospital Yonsei University Health System
-
Seoul, Coréia do Sul, 06351
- Samsung Medical Center
-
-
-
-
California
-
West Hollywood, California, Estados Unidos, 90048
- Cedars Sinai Medical Center
-
-
Indiana
-
Indianapolis, Indiana, Estados Unidos, 46256
- Community Health Network
-
-
New York
-
New York, New York, Estados Unidos, 10016
- Langone Health at NYC University, NYU School of Medicine
-
-
Oregon
-
Portland, Oregon, Estados Unidos, 97213
- Providence Portland Medical Center
-
-
Tennessee
-
Nashville, Tennessee, Estados Unidos, 37203
- Sarah Cannon Research Institute
-
-
-
-
-
Manchester, Reino Unido, M20 4BX
- The Christie Nhs Foundation Trust
-
Sutton, Reino Unido, SM2 5PT
- Royal Marsden Hospital
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion criteria:
- Part 1 and Part 2: Participant must have histologically or cytologically confirmed solid malignancy that is metastatic or unresectable and which may derive benefit from epidermal growth factor receptor (EGFR) or mesenchymal-epidermal transition tyrosine kinase receptor/hepatocyte growth factor receptor (cMet) directed therapy. Eligible tumor types include non-small cell lung cancer (NSCLC), squamous cell carcinoma of the head and neck (SCCHN), hepatocellular cancer (HCC), colorectal cancer (CRC), renal cell cancer (RCC), medullary thyroid cancer (MTC), gastroesophageal cancer (GEC), mesothelioma, breast cancer (BC) and ovarian cancer (OC). Participants must have either progressed after prior standard of care therapy for metastatic disease, be ineligible for, or have refused all other currently available therapeutic options. In cases where participants refuse currently available therapeutic options, this must be documented in the study records.
- Participant must have Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
- A woman of childbearing potential must have a negative serum (beta-human chorionic gonadotropin [beta-hCG]) at Screening and a negative urine or serum pregnancy test within 24 hours before the first dose of study drug
- A woman must agree not to donate eggs (ova, oocytes) for the purposes of assisted reproduction during the study and for 6 months after receiving the last dose of study drug
- A man who is sexually active with a woman of childbearing potential must agree to use a condom and his partner must also be practicing a highly effective method of contraception (that is, established use of oral, injected or implanted hormonal methods of contraception; placement of an Intrauterine device [IUD] or Intrauterine system [IUS])
Exclusion criteria:
- Participant has uncontrolled inter-current illness, including but not limited to poorly controlled hypertension or diabetes, ongoing or active systemic infection (that is, has discontinued all antibiotics for at least one week prior to first dose of study drug), diagnosed or suspected viral infection (except Human immunodeficiency virus [HIV] positive participants with 1 or more of the following: a) not receiving highly active antiretroviral therapy; b) a change in antiretroviral therapy within 6 months of the start of screening; c) cluster of differentiation 4 (CD4)+ T-cell count less than [<]350 per cubic millimeters [mm^3] at screening; d) an acquired immunodeficiency syndrome-defining opportunistic infection within 6 months of the start of screening), or psychiatric illness/social situation that would limit compliance with study requirements, including ability to self-care for anticipated toxicities [that is. rash or paronychia]. Participants with medical conditions requiring chronic continuous oxygen therapy are excluded
- Participant has had prior chemotherapy, targeted cancer therapy, or treatment with an investigational anti-cancer agent within 2 weeks or 4 half-lives, whichever is longer, before the first administration of study drug; or participant has received prior immunotherapy within 6 weeks before the first administration of study drug. For agents with long half-lives, the maximum required time since last dose is 4 weeks. Toxicities from previous anticancer therapies should have resolved to baseline levels or to Grade 1 or less, (except for alopecia [any grade], Grade less than or equal to [<=] 2 peripheral neuropathy, and Grade less than [<] 2 hypothyroidism stable on hormone replacement). Autoimmune toxicities from previous immunotherapy must be fully resolved to baseline levels
- Participants with untreated brain metastases. Participants with locally treated metastases that are clinically stable and asymptomatic for at least 2 weeks and who are off or receiving low-dose corticosteroid treatment (<=10 milligrams [mg] prednisone or equivalent) for at least 2 weeks prior to study treatment are eligible
- Participant has an active malignancy other than the disease under study requiring treatment
- Participant has leptomeningeal disease
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Não randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: Part 1: Ami-LC-MD and Ami-LC
Participants in cohort 1a will receive amivantamab admixed with rHuPH20 (Ami-LC-MD) subcutaneous (SC) infusion and participants in cohort 1b will receive amivantamab (Ami-LC) SC infusion. |
Participants will receive amivantamab admixed with rHuPH20 SC infusion. Participants will receive amivantamab SC infusion. |
|
Experimental: Part 2: Ami-HC and Ami-HC-CF
Participants will receive SC infusion of newly developed high concentration amivantamab (Ami-HC) or SC injection of amivantamab co-formulated with rHuPH20 (Ami-HC-CF). |
Participants will receive amivantamab SC infusion. Participants will receive amivantamab co-formulated with rHuPH20 as SC injection. |
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Observed Amivantamab Serum Concentration Immediately Prior to the Next Dose Administration (Ctrough)
Prazo: Up to Day 29
|
Ctrough is the observed amivantamab serum concentration immediately prior to the next drug administration. |
Up to Day 29
|
|
Number of Participants with Adverse Event (AE)
Prazo: Up to 4 years 1 month
|
An adverse event is any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non-investigational) product. An adverse event does not necessarily have a causal relationship with the drug. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal finding), symptom, or disease temporally associated with the use of a medicinal (investigational or non investigational) product, whether or not related to that medicinal (investigational or non-investigational) product. |
Up to 4 years 1 month
|
|
Number of Participants with Dose Limiting Toxicity (DLT)
Prazo: Up to Day 28
|
Number of participants with DLT will be assessed. |
Up to Day 28
|
|
Number of Participants with Clinical Laboratory Abnormalities
Prazo: Up to 4 years 1 month
|
Number of participants with clinical laboratory (hematology, clinical chemistry, and urinalysis) abnormalities will be assessed. |
Up to 4 years 1 month
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Number of Participants with Anti-amivantamab and Anti-rHuPH20 antibodies
Prazo: Up to 4 years 1 month
|
Number of participants with anti-amivantamab and anti-rHuPH20 antibodies will be assessed. |
Up to 4 years 1 month
|
|
Epidermal Growth Factor Receptor (EGFR) Concentrations
Prazo: Up to 4 years 1 month
|
EGRF concentrations markers will be assessed. |
Up to 4 years 1 month
|
|
Mesenchymal-Epidermal Transition Tyrosine Kinase Receptor/Hepatocyte Growth Factor Receptor (cMET) Markers
Prazo: Up to 4 years 1 month
|
cMET markers will be analyzed. |
Up to 4 years 1 month
|
|
Overall Response Rate (ORR)
Prazo: Up to 4 years 1 month
|
ORR defined as the proportion of participants with partial response (PR) or better according to Response Criteria in Solid Tumors (RECIST) v1.1. |
Up to 4 years 1 month
|
|
Part 2: Maximum Amivantamab Dosing Interval Between Time Zero to Steady State
Prazo: Up to 4 years 1 month
|
Maximum amivantamab dosing interval Between time zero to steady state will be assessed. |
Up to 4 years 1 month
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Diretor de estudo: Janssen Research & Development, LLC Clinical Trial, Janssen Research & Development, LLC
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Real)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- CR108891
- 2020-003225-36 (Número EudraCT)
- 61186372NSC1003 (Outro identificador: Janssen Research & Development, LLC)
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Descrição do plano IPD
The data sharing policy of Johnson & Johnson Innovative Medicine is available at innovativemedicine.jnj.com/our-innovation/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .